Cover Image

Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Hengbang Wang, Yun Yang, Zi Chen, Lei Fu, Min Yu, Lixin Jiang, Cunlin Wang, Lichuang Men, Ilisse Minto, Dajun Yang, Yifan Zhai
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Clinical and Translational Science
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effects of a High‐Fat Meal on the Pharmacokinetics of Olverembatinib in Patients With Chronic Myeloid Leukemia
by: Hengbang Wang, et al.
Published: (2026)

The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first‐in‐class ACKR3/CXCR7 antagonist, ACT‐1004‐1239
by: Christine Huynh, et al.
Published: (2024)

Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers
by: Tianxing Liu, et al.
Published: (2024)

Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose‐escalation phase I study
by: Jia‐yu Zhang, et al.
Published: (2024)

Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data
by: Huijun Chen, et al.
Published: (2024)

Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors
by: Guihong Yang, et al.
Published: (2024)

A phase I trial assessing the safety, pharmacokinetics, cerebrospinal fluid penetrance, and food effect of BTK inhibitor tolebrutinib in healthy volunteers
by: Marie‐José Cabanis, et al.
Published: (2024)

Correction to “Clinical pharmacokinetics of atropine oral gel formulation in healthy volunteers”
Published: (2024)

Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin‐A receptor antagonist
by: Yun Liu, et al.
Published: (2024)

Pharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: A phase I single and multiple ascending dose study
by: Byung Hak Jin, et al.
Published: (2024)

Influence of novel CYP2C‐haplotype on proton pump inhibitor pharmacokinetics in children
by: Kathryn E. Kyler, et al.
Published: (2024)

Randomized, double‐blind, phase 1a single‐ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers
by: William K. Schmidt, et al.
Published: (2024)

Association of Metabolic Genotype Composite CYP3A5*3 and CYP3A4*1B to Tacrolimus Pharmacokinetics in Stable Black and White Kidney Transplant Recipients
by: Daniel Brazeau, et al.
Published: (2025)

Physiologically Based Pharmacokinetic Modeling of Valemetostat to Inform Dose Recommendations When Coadministered With CYP3A /P‐gp Modulators
by: Akiko Watanabe, et al.
Published: (2025)

No drug–drug interactions between selective prolyl‐tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants
by: Wonsuk Shin, et al.
Published: (2024)

Evaluation of drug–drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjects
by: Jingcheng Chen, et al.
Published: (2024)

Drug–drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open‐label, randomized, 6‐sequence, 3‐period crossover studies
by: Tomohiro Kamimura, et al.
Published: (2024)

A first‐in‐human, single and multiple dose study of lunsekimig, a novel anti‐TSLP/anti‐IL‐13 NANOBODY® compound, in healthy volunteers
by: Annemie Deiteren, et al.
Published: (2024)

Phenoconversion of CYP3A4, CYP2C19 and CYP2D6 in Pediatrics, Adolescents and Young Adults With Lymphoma: Rationale and Design of the PEGASUS Study
by: Rachel Conyers, et al.
Published: (2025)

A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants
by: Ana Liza Andresan Sun, et al.
Published: (2024)

Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants
by: Aarti Sawant‐Basak, et al.
Published: (2024)

Pharmacokinetic interactions between fexuprazan, a potassium‐competitive acid blocker, and nonsteroidal anti‐inflammatory drugs in healthy males
by: Heejae Won, et al.
Published: (2024)

Pharmacokinetic comparison of subcutaneously administered CT‐P13 (biosimilar of infliximab) via autoinjector and pre‐filled syringe in healthy participants
by: Ye Chan Park, et al.
Published: (2024)

Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod
by: Qiudi Jiang, et al.
Published: (2024)

Correction to “Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects”
Published: (2024)

Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants
by: Jason D. Kim, et al.
Published: (2026)

Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non‐covalent BTK inhibitor, in healthy subjects: First‐in‐human phase I study
by: Kyoko Miyamoto, et al.
Published: (2024)

The beneficial effects of neutrophil elastase inhibitor on gastrointestinal dysfunction in sepsis
by: Jia‐Kui Sun, et al.
Published: (2024)

Association of CYP2C19 genotypes with postoperative atrial fibrillation after coronary artery bypass surgery
by: Qin Jiang, et al.
Published: (2024)

Safety, pharmacokinetics, and pharmacodynamics of ART‐648, a PDE4 inhibitor in healthy subjects: A randomized, placebo‐controlled phase I study
by: Akira Tanaka, et al.
Published: (2024)

Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole
by: Sylvia D. Klomp, et al.
Published: (2024)

Impact of CYP2D6 and CYP2B6 phenotypes on the response to tramadol in patients with acute post‐surgical pain
by: Ana Casajús, et al.
Published: (2024)

Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor
by: Zi‐Yang Shi, et al.
Published: (2024)

A novel mechanism for maintaining spindle normality in mammalian oocytes
by: Zhi‐Xia Yang, et al.
Published: (2025)

Hemodynamic and Pharmacokinetic Interactions of TPN171 with Alcohol in Healthy Male Subjects
by: Jie Cheng, et al.
Published: (2025)

Pharmacokinetics as a Biomarker
by: John A. Wagner, et al.
Published: (2026)

Population Pharmacokinetics and Exposure–Response Analysis of Serplulimab in Small Cell Lung Cancer Patients
by: Kun Wang, et al.
Published: (2025)

Population Pharmacokinetic and Pharmacokinetic‐Pharmacodynamic Modeling of Serum M‐Protein Response for Modakafusp Alfa in a Phase 1/2 Study of Patients With Relapsed or Refractory Multiple Myeloma
by: Cheryl Li, et al.
Published: (2025)

A Modeling Investigation of the CYP1A Drug Interactions of Riluzole
by: Paul Malik, et al.
Published: (2025)

In vitro comparative analysis of metabolic capabilities and inhibitory profiles of selected CYP2D6 alleles on tramadol metabolism
by: Noor Ahmed Nahid, et al.
Published: (2025)